Back to search results

Registry for T-cell Lymphoma

This study is creating a registry (a collection of information) to better understand T-cell lymphoma, NK-cell lymphoma, T-cell prolymphocytic leukemia, T-cell large granular lymphocytic leukemia, and chronic lymphoproliferative disorder of NK cells. Researchers hope to use this information to improve outcomes for people with these conditions. You might be able to join if you have one of these diagnoses and provide consent. The study is considered successful if 1000 participants contribute to the registry over 10 years. The current recruitment status is unclear.

Study design
This is an observational study aiming to enroll 1000 participants. It is a registry, meaning it collects information without testing a specific treatment.
What's involved
You would provide written informed consent and an adequate tumor biopsy. You may also be asked to provide optional blood and nail samples for future research.
Compensation
Not stated in the trial record.
Follow-up
The primary goal is measured at 10 years, indicating a long-term collection of information.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT05978141

A Registry for People With T-cell Lymphoma

Recruiting
Not specifiedAll AgesObservational
Memorial Sloan Kettering Cancer Center
~1,000 participants
Updated 2026-05-20 on ClinicalTrials.gov
What's tested:Optional Blood Sample and Nail Sample

At a glance

Recruiting sites
6 of 26 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Number of participants populating the T-cell Lymphoma Master Repository/TCLMR
Measured over 10 years

Conditions

T-cell Lymphoma
NK-Cell Lymphoma
T-cell Prolymphocytic Leukemia
T-cell Large Granular Lymphocytic Leukemia
Chronic Lymphoproliferative Disorder of NK Cells
Aggressive NK-cell Leukemia
Systemic Epstein-Barr Virus Positive T-Cell Lymphoproliferative Disease of Childhood (Disorder)
Systemic Epstein Barr Virus Positive T-Cell Lymphoproliferative Disease of Childhood
Chronic Active EBV Infection of T-and NK-Cell Type, Systemic Form
Hydroa Vacciniforme-Like Lymphoproliferative Disorder
Adult T-cell Leukemia/Lymphoma
Extranodal NK/T-cell Lymphoma, Nasal Type
Enteropathy-associated T-cell Lymphoma
Monomorphic Epitheliotropic Intestinal T-Cell Lymphoma
Intestinal T-Cell Lymphoma, Not Otherwise Specified
Indolent T-Cell Lymphoproliferative Disorder of the Gastrointestinal Tract
Hepatosplenic T-cell Lymphoma
Subcutaneous Panniculitis-Like T-Cell Lymphoma
Mycosis Fungoides
Sezary Syndrome
Primary Cutaneous Anaplastic Large Cell Lymphoma
Primary Cutaneous T-cell Lymphoma
Primary Cutaneous CD8-Positive Aggressive Epidermotropic T-Cell Lymphoma
Primary Cutaneous Acral CD8-Positive T-Cell Lymphoma
Peripheral T-Cell Lymphoma, Not Otherwise Specified
Angioimmunoblastic T-cell Lymphoma
Follicular T-Cell Lymphoma
Nodal Peripheral T-Cell Lymphoma With TFH Phenotype
Anaplastic Large Cell Lymphoma, ALK-Positive
Anaplastic Large Cell Lymphoma, ALK-negative
Breast Implant-Associated Anaplastic Large Cell Lymphoma

Explore related trials

Adult T-Cell Leukemia/LymphomaAggressive NK-Cell LeukemiaAnaplastic Large Cell LymphomaBreast Implant-Associated Anaplastic Large Cell LymphomaChronic Active EBV DiseaseChronic Lymphoproliferative Disorder of NK-CellsEBV-Positive T-Cell/NK-Cell Lymphoproliferative Disorder of ChildhoodEnteropathy-Associated T-Cell LymphomaFollicular Helper T-Cell Lymphoma, Angioimmunoblastic-TypeFollicular Helper T-Cell Lymphoma, Follicular-TypeHepatosplenic T-Cell LymphomaHydroa Vacciniforme Lymphoproliferative DisorderIndolent Clonal T-Cell Lymphoproliferative Disorder of the Gastrointestinal TractIntestinal T-Cell LymphomaMature T-Cell and NK-Cell Non-Hodgkin LymphomaMonomorphic Epitheliotropic Intestinal T-Cell LymphomaMycosis FungoidesNasal Type Extranodal NK/T-Cell LymphomaPrimary Cutaneous Acral CD8-Positive T-Cell Lymphoproliferative DisorderPrimary Cutaneous Anaplastic Large Cell LymphomaPrimary Cutaneous CD8-Positive Aggressive Epidermotropic Cytotoxic T-Cell LymphomaPrimary Cutaneous Gamma-Delta T-Cell LymphomaSezary SyndromeSubcutaneous Panniculitis-Like T-Cell LymphomaT-Cell Large Granular Lymphocyte LeukemiaT-Cell Prolymphocytic Leukemia

Where it's being run

26 sites across 15 states
New York5
California4
Florida2
Massachusetts2
New Jersey2
Pennsylvania2
Colorado1
Connecticut1

Study leadership

  • Steven Horwitz, MD · PRINCIPAL_INVESTIGATOR · Memorial Sloan Kettering Cancer Center

Who to contact

Steven Horwitz, MD
[email protected]
646-608-2680
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Written informed consent
Adequate fresh or archival tumor biopsy or intent to obtain fresh tumor biopsy.
Pathologically-confirmed mature T- or natural killer (NK)-cell lymphoma meeting one of the following diagnostic criterion (based on WHO classification and NCCN guidelines):
T-cell prolymphocytic leukemia
T-cell large granular lymphocytic leukemia
Chronic lymphoproliferative disorder of NK cells
Aggressive NK-cell leukemia
Systemic Epstein-Barr virus (EBV)-positive T-cell lymphoma of childhood
Chronic active EBV infection of T- and NK-cell type, systemic form
Hydroa vacciniforme-like lymphoproliferative disorder
Adult T-cell leukemia/lymphoma
Extranodal NK/T-cell lymphoma, nasal type
Enteropathy-associated T-cell lymphoma
Monomorphic epitheliotropic intestinal T-cell lymphoma
Intestinal T-cell lymphoma, not otherwise specified (NOS)
Indolent T-cell lymphoproliferative disorder of the gastrointestinal tract
Hepatosplenic T-cell lymphoma
Subcutaneous panniculitis-like T-cell lymphoma
Mycosis fungoides (limited to those with ≥ stage IB disease and those receiving active therapy)
Sézary syndrome
Primary cutaneous anaplastic large cell lymphoma (receiving systemic therapy)
Primary cutaneous Gamma-Delta T-cell lymphoma
Primary cutaneous CD8+ aggressive epidermotropic cytotoxic T-cell lymphoma
Primary cutaneous acral CD8+ T-cell lymphoma (receiving systemic therapy)
Peripheral T-cell lymphoma, not otherwise specified
Angioimmunoblastic T-cell lymphoma
Follicular T-cell lymphoma
Nodal peripheral T-cell lymphoma with TFH phenotype
Anaplastic large cell lymphoma, ALK-positive
Anaplastic large cell lymphoma, ALK-negative
Breast-implant associated anaplastic large cell lymphoma.
NOTE: Patients with diagnoses of mycosis fungoides, primary cutaneous anaplastic large cell lymphoma, and/or primary cutaneous acral CD8+ T-cell lymphoma must be receiving systemic therapy.

Exclusion

Patients with of mycosis fungoides, primary cutaneous anaplastic large cell lymphoma, and/or primary cutaneous acral CD8+ T-cell lymphoma not receiving systemic therapy.
Inability to collect prospective data, measure response, or perform adequate follow-up assessments in the clinical judgment of the treating physician. NOTE: Repository participation does not exclude participation in clinical trials, nor does existing clinical trial participation exclude enrollment in the study herein outlined.

What this trial measures

  • Number of participants populating the T-cell Lymphoma Master Repository/TCLMR10 years

    To develop and populate a secure database comprised of patients with T-cell lymphomas with curated clinical characteristics and treatment outcomes matched to pathological biospecimens.